In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Phpositive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to be a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation. Leukemia (2001) 15, 575-582.
Introduction
The Philadelphia chromosome (Ph) has been implicated as the causative factor in greater than 90% of chronic myelogenous leukemia (CML), in 25-30% of adult and 2-10% of childhood acute lymphoblastic leukemia (ALL) and in rare cases of acute myelogenous leukemia (AML). 1 The BCR-ABL fusion oncoprotein, the product of the Ph chromosome, exists in three principal forms (P190, P210 and P230) that arise from distinct breakpoints in the BCR gene on chromosome 22 . 2 In addition, a variant with a fusion protein of intermediate size between P210 and P190 has recently been described. 3 The two common breakpoint cluster regions are localized on the long arm of chromosome 22: the major breakpoint cluster region (Mbcr) of 5.8 kb which maps between exons 12 and 15 of the BCR gene 4 and the minor breakpoint cluster region (m-bcr) which lies in a region of 35 kb on the first intron of the BCR gene. 5 Translocation of BCR exons 1-12/13 on chromosome 22 to the ABL1 exon 2 on chromosome 9 results in a hybrid 8.5 kb messenger RNA that encodes a 210 kDa fusion protein. 6, 7 In the 8. to exon 2 of ABL1 results in a smaller 7.5 kb mRNA, e1a2 transcript, which encodes a 190 kDa fusion protein. [8] [9] [10] Thus, the BCR-ABL oncoproteins contain the same portion of the ABL1 in the COOH terminus but differ in the amounts of BCR sequence at the NH 2 terminus (Figure 1 ).
There is evidence that the different forms of BCR-ABL are associated with distinct forms of leukemia. The P210 form of BCR-ABL is found in hematopoietic cells of patients with CML, and in acute lymphoid and myeloid leukemias. In contrast, the P190 form of BCR-ABL is rarely observed in CML, but is commonly found in Ph-positive ALL and occasionally in AML. 2 Two models have been proposed to explain this fact. One possibility is that the two forms of BCR-ABL have different intrinsic leukemogenic activities when expressed in a hematopoietic progenitor cell that has acquired the translocation. Alternatively, the two oncogenes may have identical leukemogenic properties, but their expression might be largely restricted to different hematopoietic lineages because during the formation of the Ph chromosome a particular breakpoint is favored in a given lineage.
We have previously shown that the proximal promoter of the ABL1 oncogene undergoes de novo methylation upon clinical progression of CML. DNA samples of patients that are methylation-free at the time of diagnosis invariably become methylated at blast crisis. 11, 12 We have also shown that methylation of ABL1 is gene specific and does not reflect a generalized process. 13 In blast crisis CML cell lines, the methylation is associated with block of ABL1 transcription: even multiple copies of methylated ABL1 promoter yielded no mRNA or protein expression. 11 We have suggested that methylation of the ABL1 promoter prevents expression from the normal ABL1 allele within the translocation and thus decreases the ratio of expression between ABL1, a tumor suppressor gene, and BCR-ABL, an oncogene, in the affected cells. This raises the question of whether a similar epigenetic modification occurs on the Ph chromosome in Ph-positive ALL. In an attempt to address this issue we have investigated the pattern and abundance of ABL1 promoter methylation in samples from patients with Ph-positive ALL. These results are compared to our data from chronic, accelerated and blastic crisis phases of CML. In addition, we have analyzed the methylation pattern of ATM and several DNA repair genes, hMSH2, hMSH6 and hMLH1, in the same set of samples.
Materials and methods

Patient samples
The diagnosis of ALL as opposed to lymphoblastic transformation of CML in the patients in this work was established based on clinical and laboratory data. All our Ph-positive ALL patients temporarily achieved complete hematological, as well as cytogenetic remission upon treatment, which points
Figure 1
The major forms of BCR-ABL fusion gene. Breakpoints in the m-bcr region of the BCR gene result in fusion of the first exon of this gene (e1) with the second exon of the ABL1 gene (a2) to form the e1a2 BCR-ABL transcript which encodes the P190 hybrid protein. Breakpoints in the M-bcr region of the BCR gene lead to joining of the second or third exons of this region (b2, b3) with the second exon of the ABL1 gene (a2) to form the b2a2 or b3a2 transcripts which are translated into the P210 product.
to ALL rather than CML. The CML study cohort included 12 untreated patients at diagnosis of the chronic phase CML and seven patients with accelerated phase or blastic crisis CML.
Cell isolation and DNA extraction from clinical samples
Mononuclear layers of peripheral blood or bone marrow cells were isolated on a Ficoll-Paque (Amersham, Uppsala, Sweden) density gradient. Genomic DNA was subsequently extracted using standard organic extraction procedures.
Bisulfite modification of DNA
Genomic DNA was modified by sodium bisulfite as previously described. 13 Briefly, 5 g DNA per reaction were denatured at 95°C for 15 min. Samples were subsequently chilled on ice for 2 min and 2 N freshly prepared NaOH was added to a final concentration of 0.5 N in a total volume of 30 l. After a 15-min incubation at 37°C, 450 l of freshly prepared bisulfite reagent were added and the mixtures were overlaid with mineral oil and allowed to incubate at 55°C for 4 h. Following incubation, DNA was extracted using the Wizard DNA Clean-up kit (Promega, Madison, WI, USA). Purified DNA was recovered in water and 2 N NaOH added to a final concentration of 0.3 N; samples were allowed to incubate for 15 min at 37°C. On conclusion of this step, 1-1.5 g of lambda DNA (NEB, Beverly, MA, USA) were added and the DNA was ethanol precipitated overnight at −80°C. DNA was subsequently recovered by centrifugation and dissolved in sterile water in preparation for PCR. The bisulfite reagent was prepared as follows: to 1.9 g of sodium bisulfite (Sigma, St Louis, MO, USA) 1 ml of sterile water, 0.7 ml of 2 N NaOH, and 0.5 ml of a saturated solution of hydroquinone (Sigma) are added. Then sterile water is added to a total volume of 4 ml and the reagents are mixed on a gentle rocker until dissolved.
Methylation-specific PCR (MSP)
For the ABL1, hMSH2 and hMSH6 loci, a single step MSP approach was used. For ATM and hMLH1, a two-step PCR approach was employed. 50 ng of genomic DNA modified as above were included in 50 l PCR reaction volumes containing buffer to 1 × final concentration (Tris-HCl 10 mM pH 9, KCl 50 mM, MgCl 2 1.5 mM, Triton X100 0.1%, BSA 0.2 mg/ml), primers (25 pmoles) and 2 U of Taq polymerase (Appligene-Oncor, Illkirch, France). dNTP concentrations were calibrated for each PCR reaction as a way to achieve gentle adjustments of the magnesium concentration. For specific conditions and primer sequences see Asimakopoulos et al. 13 As a positive control, DNA from normal donor buffy coat samples was in vitro methylated at CpG sites using CpG methylase (SssI methylase) (NEB) as per manufacturer's recommendations.
Sequencing of bisulfite modified DNA
In order to amplify the entire ABL1 CpG island, primers specific to bisulfite modified DNA, but not methylation-specific, were used (ABL1 island primers 13 ). The PCR products were cloned using a TOPO TA cloning kit (Invitrogen BV, Leek, The Netherlands). Individual clones were screened for the presence of a full length insert by PCR using primers specific for the cloning vector. Methylation status of individual clones was determined by performing MSP on the PCR product of the full insert using the following primers: 5Ј acttctaaaataaaataaaacaaa 3Ј and 5Ј cgcggtcgcgttttcgtttggtcgggacgc 3Ј. The PCR products of the full length insert were then sequenced directly on an automated sequencer using a primer specific for the cloning vector.
Sequencing data analysis
Sequences of individual clones were compared with controls using William Pearson's LALIGN program at www.isrec.isbsib.ch; multiple clone alignment was performed with BCM Search Launcher at dot.imgen.bcm.tmc.edu.
Statistical analysis
P value for association of ABL1 promoter methylation with type of transcript was obtained with chi-squared test. P values for the rest of the parameters (age, blasts, WBC, LDH) were calculated using t-test assuming equal variances of the two samples.
Results
Association of ABL1 promoter methylation with the P210 and not the P190 form of BCR-ABL in ALL
In order to determine whether in Ph-positive ALL the proximal promoter of the ABL1 gene is methylated, we used methylation-specific PCR (MSP). This is a highly sensitive technique, which allows the detection of both methylated and unmethylated alleles in a given sample. DNA samples from 18 patients diagnosed with Ph-positive ALL (Table 1) were modified with bisulfite and MSP was performed as previously described. 13 We found methylation of the ABL1 promoter in six of the 18 patients' samples of Ph-positive ALL. In addition to methylated ABL1 promoters, these samples also contained unmethylated ABL1 sequences, supposedly representing the intact ABL1 (Figure 2 ). Interestingly, of the six samples which contained methylated ABL1 sequences, four were of the P210 form of BCR-ABL (b2a2 or b3a2 type transcript) and two had both the P210 and the P190 form (b3a2 and e1a2 type transcript). In contrast, of the 12 patients which did not have methylated ABL1 sequences only one was of the P210 form (b2a2 type transcript) and 11 of the P190 form (e1a2 transcript). No ABL1 promoter methylation was detected in three cases of Ph-negative ALL (Figure 2 ). Thus, there is a strong correlation between type of transcript and the presence of methylated ABL1 promoter sequences (P Ͻ 0.0002) ( Table 2 ). An analysis of clinical characteristics of these patients (age, spleen and liver size, Hb, WBC and PLT counts, percentage of blasts in bone marrow and LDH) showed no differences between patients with P190 and P210 and between patients with methylated ABL1 promoters vs unmethylated ABL1 promoters (Table 2 ). This is in agreement with previous studies showing no correlation between different transcripts in Phpositive acute leukemia and patient clinical characteristics or laboratory features.
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Figure 2
Detection of ABL1 promoter methylation in ALL clinical samples. Methylation-specific PCR was performed on the following samples: P210 Ph + ALL, P210 Ph-positive ALL samples; P190 Ph + ALL, P190 Ph-positive ALL samples; Ph − ALL, Ph-negative ALL sample; NBC, normal donor buffy-coat DNA; SssI NBC, normal donor buffycoat DNA pretreated in vitro with CpG methylase (SssI methylase). ⌽x, ⌽x/HaeIII marker; M, primers specific for methylated DNA; U, primers specific for unmethylated DNA. 
ABL1 promoter methylation is of high density and no distinct topology both in ALL and CML
We then sought to investigate the extent and topology of ABL1 methylation in 10 representative cases of Ph-positive ALL (four methylated and six methylation-free samples according to MSP). We were also interested in comparing the pattern of methylation observed in ALL to that found in CML samples. For this purpose we studied 12 pretreatment samples of chronic phase CML (CP CML) and seven cases of advanced CML (A CML) (accelerated phase and blastic crisis CML). We employed bisulfite sequencing in order to detect CpG methylation outside a specific primer binding site and to assess quantitatively the relative abundance of the promoter methylation in a given sample. For that purpose both methylated and unmethylated ABL1 promoters were amplified from bisulfite treated DNA in a single PCR with a primer set insensitive to methylation. The products were subsequently cloned and checked for the presence of full length insert (by nested PCR) and CpG methylation (by seminested MSP). Sequencing of the representative clones showed that the unmethylated clones in all patient subgroups were completely devoid of CpG methylation throughout the entire promoter length. In contrast, the overwhelming majority of CpGs (usually Ͼ90%) were methyl- 
Figure 3
Methylation topology of the ABL1 promoter region in P210 Ph-positive ALL patient samples as determined by bisulfite sequencing. The region amplified corresponds to co-ordinates −473 to +46 with respect to the start of exon 1a or co-ordinates 37352 to 37871 of GenBank sequence U07563. 24 The relative position of dots on the diagram corresponds to the relative position of CpG dinucleotides along the island. White dots indicate methylated CpG dinucleotides; black dots indicate unmethylated CpG dinucleotides. Amplification products obtained from total peripheral blood or bone marrow mononuclear cells were cloned and individual clones were sequenced on an automated sequencer. For each patient, only clones of methylated ABL1 promoter are depicted since all unmethylated clones analyzed were completely devoid of methylation. ated in all clones predicted by MSP screening to be methylated (Table 3) . ABL1 promoter methylation topology in P210 Ph-positive ALL samples is presented in Figure 3 . Most of the sequenced clones in all samples were unique suggesting unbiased representation of various alleles. In summary, the methylated promoters from Ph-positive ALL, CP CML and A CML samples showed a widespread and overwhelming CpG methylation which lacked a distinct spatial pattern.
High abundance of ABL1 promoter methylation in acute P210 Ph-positive leukemias
In these experiments we were also able to estimate the relative abundance of the ABL1 promoter methylation in each sample by a comparison of numbers of methylated vs unmethylated clones. It should be noted that even in a 100% Ph-positive sample half of the clones are expected to represent the ABL1 allele on the intact chromosome 9. The screening results were in excellent correlation with the MSP data: each of the four methylated samples, as determined by MSP, contained 10 to 52% of methylated ABL1 promoters, whereas in the six methylation-free samples only 1% (one clone) was found by sequencing to be methylated ( Table 3 ). The relative prevalence of ABL1 methylated alleles in 173 clones of P210 Phpositive ALL (23.7%) was substantially higher than that in 170 CP CML clones (12.9%) and approximated the ratio observed in A CML (26.5%) ( Table 3) . Notably, a complete absence of methylated alleles was found in four out of 12 CP CML cases studied. Thus, acute P210 Ph-positive leukemias are characterized at a molecular level by a high frequency of ABL1 promoter methylation while CP CML samples at diagnosis display no or low levels of this epigenetic aberration.
ABL1 methylation in ALL is a gene-specific process
We then asked whether other genes may also undergo methylation in Ph-positive ALL. Methylation status of various genes such as the ataxia telangiectasia locus (ATM) and the mismatch repair genes hMLH1, hMSH6 and hMSH2 was studied using MSP. No methylation of any of these genes' promoters was detected in Ph-positive ALL samples, in agreement with our results in CML that de novo methylation of ABL1 is highly gene specific. 13 
Discussion
We and others have previously reported methylation of the ABL1 promoter in CML upon clinical progression of the disease. [11] [12] [13] 15, 16 We have demonstrated that this epigenetic alteration accounts for the loss of ABL expression in cell lines established from patients in the blastic phase of CML and suggested it may cause similar loss of expression in CML patients. This led us to address a related question: is the ABL1 promoter methylated in Ph-positive ALL? In this study we demonstrate that methylation of the ABL1 promoter in Ph-positive ALL strongly correlated with the type of translocation. We would like to propose that ABL1 promoter methylation may be an epigenetic modification associated mainly with the P210 form of BCR-ABL and not the P190 form. This is the first molecular difference that correlates with the different types of translocations in Ph-positive ALL.
The fact that CML patients almost always have the P210 form of BCR-ABL and only rarely have the P190 form has suggested that there are qualitative differences between the translocations. Previous studies have failed to identify a correlation between different messages in Ph-positive acute leukemias with patient clinical characteristics or laboratory features.
14 In vitro studies which have characterized the tyrosine kinase and transformation activities of P190 and P210 have suggested that these proteins have distinct properties, with P190 having higher tyrosine kinase activity and being more efficient in transformation of Rat-1 fibroblasts. 17, 18 In transgenic mice, Leukemia P210 and P190 have been shown to cause distinct types of leukemia although neither was able to fully reproduce a CMLlike disease. 19, 20 A mouse model using the bone marrow transduction/transplantation system has demonstrated that there is no difference in the ability of P190 and P210 to induce a CML-like myeloproliferative syndrome, but that P190 had increased potency for induction of B lymphoid leukemia. 21 It has been suggested that the restriction of P190 to human acute leukemias may be due to the cell type specificity of the form of the Ph translocation in stem cells. This is in accordance with the traditional view of ALL being restricted to the lymphoid lineage. However, recent work has shown the presence of the Ph chromosome in lineages other than lymphoid in Phpositive ALL, suggesting that leukemogenesis in Ph-positive ALL affects an early noncommitted progenitor cell, similarly to what occurs in CML. 22 The mechanism that leads to clinical expression of the disease in only lymphoid lines is still not known.
We suggest two possibilities for the difference in methylation of the P210 vs P190 form of BCR-ABL. One possibility is that the alternative breakpoints in the BCR gene, resulting in the proximity of the ABL1 promoter to different BCR sequences, are responsible for the variance in methylation status. Methylation of the proximal promoter of ABL1 may be a consequence of juxtaposition to certain upstream Alu-rich BCR regions, acting as methylation centers. 23 However, it should be noted that both ABL1 and BCR genes have an extremely high density of Alu homologous regions. 24 An alternative possibility may be that the translocation breakpoints in ABL1 are different in P190 vs P210. Most analyses of breakpoints are at the RNA level and therefore determine which exons are included but do not involve intron analysis. Whereas in CML it is known that 90% of the breakpoints fall in the first intron of ABL1, 25 in ALL this is not known for sure. Of the mapped translocation breakpoints in ALL, a few have been reported to fall outside the first intron of ABL1. 24 However, other reports have claimed that in Ph-positive ALL, as in CML, the first intron represents the major target for the translocations. 26 Further mapping of translocation breakpoints is necessary in order to determine if this is the case, although the large breakpoint region of the ABL1 gene (175 kb) makes this a difficult task.
For certain tumor suppressor genes the degree of their promoter methylation determines their transcriptional activity. 27, 28 This led us to compare the extent and topology of ABL1 promoter methylation in individual alleles from patients with P210 Ph-positive ALL and CML. Bisulfite sequencing of methylated clones demonstrated dense ABL1 promoter methylation (74 to 100% of the CpGs) common to Ph-positive ALL and all stages of CML. Although some CpGs appeared to remain unmethylated at a higher rate than others, no particular pattern was found in any of the sample subsets. Methylation topology was not identical in most of the clones indicating considerable intra-and interindividual heterogeneity and representation of different alleles in the cloning experiment. Thus, these data do not provide evidence for gradual methylation spread in the ABL1 promoter. The results may also indicate that during clonal evolution only the general level of methylation is maintained rather than an exact site-specific pattern. The topological heterogeneity and predominant nature of the epigenetic modification suggest an important role for CpG methylation density which could determine ABL1 transcription level (Table 3 ). The extensive methylation of ABL1 promoter appears to be a rather early event followed by an increase in prevalence of the methylated alleles (compare CP and A CML data in Table 3 ). These quantitative differences may also be detected using both methylation sensitive restriction enzyme based methods 11, 12, 15 and bisulfite MSP, 13 but could be obscured by certain extremely sensitive assays. 29 Since the initial PCR amplification in these cloning experiments was insensitive of the template promoter methylation, the ratio between methylated and unmethylated clones was likely to be preserved the same as in the original samples. Thus, in a sample that consists only of Ph-positive cells approximately half of the clones should represent a translocated promoter and the rest would stem from the intact ABL1 allele. Therefore, our finding that the prevalence of the methylated allele rarely reaches the level of 50% (Table 3) correlates well with our previous observation that single CML hematopoietic progenitor-derived colonies always contain at least one unmethylated ABL1 allele. Furthermore, the absence of the promoter methylation in three Ph-negative ALL samples reported here strengthens our suggestion that the intact ABL1 allele remains free of methylation during malignant transformation. 13 Given this notion is correct, the fact that approximately 25% of the clones are methylated in P210-positive ALL and A CML indicates that on average half of the translocated ABL1 promoters undergo de novo methylation by the time an acute leukemia is present. A smaller proportion of methylated ABL1 alleles in CP CML may reflect an intermediate step in the disease molecular pathogenesis: a selective pressure for ABL1 epigenetic inactivation could lead to a subsequent clonal expansion due to an increased ratio between BCR-ABL oncoprotein and cell cycle-controlling normal ABL1 product. Alternatively, the gradual increase in ABL1 methylation may be viewed as a 'molecular clock' driven by stochastic methylation events accumulating alongside leukemia pathogenesis. However, the rapid time course of P210-positive ALL as compared with the gradual development of advanced CML may necessitate a change in the 'clock rate' which might be explained by differences in additional aberrations. Given the apparent lack of prolonged preleukemic state in P210-positive ALL, the high frequency of ABL1 promoter methylation in this quickly emerging disease is more likely to reflect a direct role in pathogenesis rather than merely being a by-product. Interestingly, the sole survivor out of the 18 Ph-positive ALL patients was also the only one of the P210 type without ABL1 promoter methylation.
Studies using MSH2 and MSH6-deficient mice clearly establish a link between mismatch repair gene defects and development of lymphoid tumors. [30] [31] [32] Mutations of the mismatch repair genes have not been reported in ALL, however a recent report has shown loss of heterozygosity of microsatellite markers closely linked to the mismatch repair genes hMLH1, HMSH2 and PMS2 in four out of six replication errorpositive ALLs. 33 Methylation of mismatch repair genes has so far been reported only for hMLH1 in solid tumors such as colon, endometrial and gastric cancers, and is almost always associated with microsatellite instability. [34] [35] [36] [37] In agreement with these reports, we did not find methylation of the promoters of DNA repair genes in ALL. However, methylation as a means to inactivate genes has been demonstrated in ALL for the calcitonin, p15 and p16 genes. [38] [39] [40] [41] More recently, methylation of p73, a target of the ABL kinase, has been reported in approximately 30% of ALLs and Burkitt's lymphomas, 42 suggesting that methylation could be a mechanism of gene silencing of tumor suppressor genes in these diseases. The ATM gene deficient in ataxia-telangiectasia, a recessive multisystem disease associated with a high risk of lymphomas and leukemias, was found previously to be inactivated in a A proposed model of leukemia pathogenesis following emergence of the Ph chromosome. The more potent P190 form of BCR-ABL can lead to ALL without an additional epigenetic modification (empty arrow), whereas P210 requires extensive methylation of ABL1 promoter (black on the diagram) for causing an acute leukemia. The prevalence of methylated clones appears to increase rapidly in P210 Ph-positive ALL and more gradually during evolution of CML (as depicted by differences in gradient of black fill in the corresponding arrows).
rare sporadic malignancy, T cell prolymphocytic leukemia (T-PLL). 43 However, no extensive hypermethylation of ATM was found in nine T-PLL tumor DNA samples. 44 Similarly, we did not find methylation of the ATM promoter in Ph-positive ALL samples.
We have previously demonstrated that methylation of the ABL1 promoter is responsible for shutting down transcription of this tumor suppressor gene from the proximal promoter of the translocated allele. This epigenetic change is an important step in the progression of CML from chronic phase to blastic crisis. We hypothesized that this might also be a crucial step in the development of Ph-positive ALL. In light of our present results, indicating that gene-specific methylation of the ABL1 promoter is restricted to the P210 form, and previous reports that P190 is more oncogenic than P210, 17, 18 we would like to put forth a model (Figure 4) . We propose that the P190 form of BCR-ABL without the epigenetic modification can lead to development of acute leukemia, as is seen in P190 Ph-positive ALL. On the other hand, P210 may require an additional modification by methylation in order to result in acute leukemia. We found significant methylation of ABL1 promoter to be a nearly ubiquitous event in P210 Ph-positive acute leukemias. The prevalence of the methylated clone may reflect the stage of the disease. This is suggested by our findings of a high percentage of methylated clones in P210 Ph-positive ALL and accelerated phase or blastic crisis of CML and no or low levels of methylated alleles in chronic phase CML. Differences in temporal course of methylation or additional changes may account for the observed differences in methylation levels. Further study of ABL1 methylation mechanisms and the resulting phenotype will contribute to identification of distinctive characteristics of ALL and CML pathogeneses.
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